Genentech Restricts Population In Last-Ditch Bid To Keep Avastin’s Breast Cancer Claim

Genentech’s last-ditch bid to retain Avastin’s metastatic breast cancer claim expands upon discussions at FDA’s June 28-29 hearing about targeted subpopulations and labeling revisions, but breaks little new ground.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet